Poster Abstract Session:
149. HAI: C. difficile Epidemiology, Impact, and Testing
Friday, October 6, 2017: 12:30 PM-2:00 PM
Room: Poster Hall CD

Tracks: Investigative ID, Epidemiology and Infection Control, Adult ID, Pediatric ID


Presentations:
Epidemiology and Outcomes of Clostridium difficile Infection in Hospitalized Patients within the US Military Health Care System
Matthew Eberly, MD; Apryl Susi, MS; Michael Rajnik, MD; Daniel Adams, MD; Cade Nylund, MD
Clostridium Difficile Infection in Hematopoietic Stem Cell Transplant Patients: A Single-Center experience.
Aneela Majeed, MD; Marti Larriva, PharmD; Ahmad Iftikhar, MD; Adeela Mushtaq, MD; Nida Hassan, Undergraduate Student; Auon A Hamadani, MD; Nageena Khalid, Graduate student; Melissa Lim, Graduate Student; Tirdad Zangeneh, DO; Faiz Anwer, MD
Longitudinal Trends of Clostridium difficile infection (CDI) within Department of Veterans Affairs (VA) Medical Centers—Acute Care and Long Term Care
Stephen Kralovic, MD, MPH, FSHEA; Martin Evans, MD, FIDSA, FSHEA; Loretta Simbartl, MS; Gary Roselle, MD, FIDSA
Epidemiologic Trends in Clostridium difficile Isolate Ribotypes in United States from 2010-2014
David R Snydman, MD; Laura A McDermott, MT(ASCP); Stephen G Jenkins, PhD; Ellie J C Goldstein, MD, FIDSA, FSHEA; Robin Patel, MD, FIDSA, D(ABMM); Betty A Forbes, Ph.D, D(ABMM), F(AAM); Stuart Johnson, MD, FIDSA; Dale N Gerding, MD, FIDSA; Cheleste M. Thorpe, MD; Seth T Walk, PhD
Epidemiology of Clostridium difficile infection Among Patients with Newly Diagnosed or Relapsed Acute Leukemia: A Single Center Experience.
Alexandra Franco Garcia, MD; Tracy McMillen, BS; Hoi Yan Chow, MS; Janet Eagan, RN, MPH, CIC; Janine Sun, BS; Mini Kamboj, MD
Incidence of Pediatric Community Associated Clostridium Difficile Infection Following Common Antibotics
Margot Miranda Katz, none; Deepika Parmar, MD; Rebecca Dang, MD; Amy Alabaster, PhD; Tara Greenhow, MD
Declining rates of Clostridium difficile infections (CDI) in Veterans Affairs (VA) long-term care facilities (LTCF)
Martin Evans, MD, FIDSA, FSHEA; Loretta Simbartl, MS; Maninder Singh, MBBS, MPH; Stephen Kralovic, MD, MPH, FSHEA; Gary Roselle, MD, FIDSA
Posters
  • Evans poster.pdf (254.9 kB)
  • A 10-year Review of Clostridium difficile Infection in Acute Care Hospitals in the United States
    Ruihong Luo, MD; Tamar Barlam, MD, MSc, FIDSA, FSHEA; Janice Weinberg, ScD
    Impact of Clostridium difficile infection on patients’ quality of life: a French Hospital prospective study
    Frederic Barbut, PharmD, PhD; Tatiana Galperine, PharmD, PhD; Philippe Vanhems, MD, PhD; Alban Le Monnier, PharmD, PhD; Viviane Jeanbat, PhD; Anne Duburcq, MSc; Sarah Alami, MSc; Caroline Bensoussan, MD; Francis Fagnani, PhD
    The Clostridium difficile Infection – Daily Symptoms (CDI-DaySyms™) Patient-Reported Outcome (PRO) Questionnaire: Final Validation and Responder Thresholds
    George H. Talbot, MD; Leah Kleinman, Dr PH; Evan W. Davies, MSc; Elke Hunsche, PhD; Laurie Roberts, MPH; Carl Erik Nord, MD, PhD, FIDSA
    Clostridium difficile Testing Algorithm: Is There a Difference in Patients Who Test Positive by Enzyme Immunoassay vs. Those Who Only Test Positive by Nucleic Acid Amplification Methodology?
    Jonathan Polak, MD; Ogheneruona Odili, MD; Mary Ashleigh Craver, MS; Anthony Mayen, BS; Kyle Purrman, BS/BA; Asem Rahman, MS; Charlie Joseph Sang III, BS; Paul P. Cook, MD
    Toxin detection by cell culture neutralization assay [CYT] and Toxin based EIA [Tox EIA] among recurrent episodes of CDI diagnosed by PCR
    Mini Kamboj, MD; Tracy Mcmillen, BS; Hoi Yan Chow, MS; Jennifer Brite, DPH; N. Esther Babady, Ph.D
    PCR Cycle-Threshold-Derived Toxin Identifies Patients at Low-Risk for Complications of C. difficile Infection Who Do Not Require Treatment
    Matthew Hitchcock, MD, MPH; Marisa Holubar, MD, MS; Lucy Tompkins, MD, PhD, FSHEA, FIDSA; Niaz Banaei, MD
    Posters
  • IDWeek_Hitchcock_Final.pdf (784.4 kB)
  • Clinical Correlation of a Clostridium difficile Testing Algorithm Reflexing PCR Positive Specimens to Toxin Enzyme Immunoassay (EIA)
    Maria Bueno Rios, MD; James Karichu, MT (ASCP); Abhishek Deshpande, MD, PhD; Thomas Fraser, MD; Carlos Isada, MD, FACP, FCCP; Sandra S. Richter, MD
    Clinical characteristics and outcomes of hematologic malignancy patients with Clostridium difficile toxin EIA versus PCR positive test results
    Matthew Ziegler, MD; Daniel Landsburg, MD; David Pegues, MD, FIDSA, FSHEA; Kevin Alby, PhD; Cheryl Gilmar, MS, MT, CIC; Kristen Bink, MSN, RN, AGCNS-BC; Theresa Gorman, MSN, RN, AOCNS; Amy Moore, MSN, RN, ACNS-BC; Jennifer Han, MD, MSCE
    Posters
  • IDWeek Poster Final.pdf (184.5 kB)
  • Impact of a Multi-disciplinary C. difficile Action team
    Emily Heil, PharmD, BCPS-AQID; Bharathi Sivasailam, MD; SoEun Park, PharmD Candidate; Jose Diaz, MD; Erik Von Rosenvinge, MD; Kimberly Claeys, PharmD, BCPS; Teri Hopkins, PharmD, BCPS; Surbhi Leekha, MBBS, MPH
    Clostridium difficile (CD) Action Team (CDAT): An Intervention to Improve Care for Patients with a Positive CD PCR
    Theodore Markou, MD; Valeria Fabre, MD; Kathryn Dzintars, PharmD; Edina Avdic, MBA, PharmD, BCPS AQ-ID; Stephanie Shulder, PharmD; Jennifer Andonian, MPH; Clare Rock, MD MS; Sara E. Cosgrove, MD, MS
    Know When to Test: Optimizing Diagnostic Practices for Clostridium difficile Infection (CDI) Among Patients at a Tertiary-Care Cancer Center
    Anoshé Aslam, MPH; Janet Eagan, RN, MPH, CIC; Janice Kaplan, RN, CIC; Elizabeth Robilotti, MD, MPH; Tracy McMillen, BS; Monika Kamalska-Cyganik, MS, MA; Suzanne Kelson, MPH; Reshma Nevrekar, BS; Wazim Narain, PhD; Peter Stetson, MD, MA; Mini Kamboj, MD; N. Esther Babady, Ph.D
    Posters
  • 1295_IDWPOSTER.jpg (748.5 kB)
  • The Impact of Diagnostic Stewardship on Clostridium difficile Infections
    Werner Bischoff, MD, PhD, FSHEA; Andrey Bubnov, .; Elizabeth Palavecino, MD; James Beardsley, PharmD; John Williamson, PharmD; James Johnson, PharmD; Vera Luther, MD; Christopher Ohl, MD, FIDSA; Guy El Helou, MD, MSc; Glen Huang, DO; John Stehle Jr., PhD, CIC; John Sanders, MD, MPH
    Posters
  • Bischof_C diff_.pdf (223.2 kB)
  • Enzyme Immunoassay for C. difficile toxin reduces Lab ID events but fails to detect clinically significant C. difficile infection
    Jessica P. Ridgway, MD, MS; Cynthia Murillo, M(ASCP), CIC; Rachel Marrs, DNP, RN, CIC; Sylvia Garcia-Houchins, RN, MBA, CIC, FSHEA; Clinitka Harper, Infection Control technologist; Allison H. Bartlett, MD, MS; Emily Landon, MD
    Posters
  • IDweek 2017 Cdiff EIA final.pdf (238.0 kB)
  • Clostridium difficile Laboratory Identification Event Reporting – A Need for Diagnostic Stewardship.
    Clare Rock, MD MS; Zoi Pana, MD, MS, PhD; Surbhi Leekha, MBBS, MPH; Polly Trexler, MS, CIC; Jennifer Andonian, MPH; Avi Gadala, MS, B.Pharma; Karen C. Carroll, MD, FIDSA; Lisa L. Maragakis, MD, MPH, FIDSA, FSHEA
    An Assessment of 2016 National Healthcare Safety Network (NHSN) and National Electronic Disease Surveillance System (NEDSS) Clostridium difficile Infections (CDI) in Nebraska
    Caitlin Pedati, MD, MPH; Madison Sullivan, BA; Margaret Drake, MT, ASCP, CIC; Alison Keyser, MPH; Tom Safranek, MD; Maureen Tierney, MD, MSc

    CME Credits: Maximum of 0.00 hours of AMA PRA Category 1 Credit™


    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.